IGLV2-14 Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• The IGLV2-14 gene encodes a variable domain of the immunoglobulin lambda light chain, crucial for antibody antigen-binding specificity, and is located on chromosome 22q11.2 within the IGL locus. Its protein product forms part of the B-cell receptor (BCR) and is essential for adaptive humoral immunity.
• V(D)J recombination, mediated by the RAG1/RAG2 complex, generates diverse IGLV2-14 rearrangements, with junctional diversity in CDR3 being a major determinant of antigen specificity. This process is tightly regulated by B-cell-specific transcription factors and enhancers like Eλ.
• IGLV2-14 is implicated in B-cell malignancies such as Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma, where its mutational status can serve as a diagnostic or prognostic marker. Specific mutations are also associated with AL amyloidosis due to protein misfolding and aggregation.
• The IGLV2-14-containing BCR engages in signaling pathways initiated by Src family kinases and SYK, leading to calcium mobilization and NF-κB activation, driving B-cell proliferation and differentiation. This signaling is a target for drugs like ibrutinib (BTK inhibitor).
• Germline polymorphisms in IGLV2-14 have been linked to susceptibility to autoimmune diseases like SLE and infectious disease responses, potentially through altered self-antigen recognition or pathogen neutralization capacity.
• Therapeutic strategies targeting IGLV2-14-expressing B cells include monoclonal antibodies (e.g., anti-CD20 like Rituximab) and CAR T-cell therapy, aiming to deplete malignant clones. Investigational approaches include antibody-drug conjugates (ADCs) and bispecific antibodies.

Executive Summary & Key Metadata

The IGLV2-14 gene (Immunoglobulin Lambda Variable 2-14) encodes a variable domain of the immunoglobulin lambda light chain, a fundamental component of the adaptive immune system. This gene is part of the immunoglobulin lambda (IGL) locus on chromosome 22q11.2, a region characterized by complex recombination dynamics and significant implications for B-cell development, humoral immunity, and lymphoproliferative disorders. The protein product, when rearranged and expressed, contributes to the antigen-binding site of antibodies, determining specificity and affinity for diverse pathogens and antigens.

The IGLV2-14 gene segment is one of approximately 70–80 variable (V) gene segments within the IGL locus, of which roughly 30–40 are functional. Its protein product is a ~110-amino-acid domain that folds into a characteristic immunoglobulin beta-sandwich structure, comprising nine beta-strands arranged in two antiparallel beta-sheets. This domain forms the N-terminal portion of the light chain and contains three hypervariable complementarity-determining regions (CDRs) that mediate direct contact with antigen.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Context and Locus Architecture

The IGLV2-14 gene resides within the immunoglobulin lambda locus on the long arm of chromosome 22, specifically at cytogenetic band 22q11.2. This locus spans approximately 1.0–1.1 megabases of genomic DNA and is organized into three distinct clusters: the variable (V) region, the joining (J) region, and the constant (C) region. The V region contains the IGLV gene segments, which are arranged in a 5' to 3' orientation relative to the J-C clusters.

The IGLV2-14 gene is positioned within the proximal V cluster, approximately 30–40 kilobases upstream of the J-C region. The precise genomic coordinates (GRCh38/hg38) are approximately chr22:22,500,000–22,510,000, though the exact boundaries vary depending on the reference genome build and the specific haplotype. The gene spans approximately 1.2–1.5 kilobases of genomic DNA, including its promoter region, coding exons, and recombination signal sequences (RSS).

1.2 Gene Structure and Regulatory Elements

The IGLV2-14 gene segment exhibits the canonical structure of an immunoglobulin variable gene:

• Promoter region: Located approximately 150–200 base pairs upstream of the transcription start site (TSS). The promoter contains a conserved octamer motif (ATTTGCAT) and a TATA box-like element, both of which are recognized by B-cell-specific transcription factors, including OCT-1, OCT-2, and PU.1. These elements drive germline transcription, which is a prerequisite for V(D)J recombination.

• Leader exon (L): The first exon encodes a hydrophobic leader peptide of approximately 15–20 amino acids. This signal peptide directs the nascent polypeptide into the endoplasmic reticulum (ER) for subsequent processing and secretion. The leader exon is separated from the variable exon by a short intron of approximately 100–200 base pairs.

• Variable exon (V): The second exon encodes the mature variable domain of approximately 110 amino acids. This exon contains the three CDRs and four framework regions (FRs) that constitute the immunoglobulin fold.

• Recombination signal sequences (RSS): Located immediately 3' of the variable exon, the RSS consists of a conserved heptamer (CACAGTG) and nonamer (ACAAAAACC) separated by a 23-base-pair spacer. This 23-bp spacer classifies IGLV2-14 as a V gene that rearranges exclusively with J segments possessing a 12-bp spacer RSS, following the 12/23 rule of V(D)J recombination.

1.3 Transcription Factor Binding and Enhancer Elements

The expression of IGLV2-14 is tightly regulated by a combination of proximal promoter elements and distal enhancers. Key regulatory features include:

• Octamer motif: Binds OCT-1 (ubiquitous) and OCT-2 (B-cell-specific), which recruit co-activators such as OCA-B (OBF-1) to activate germline transcription.

• E-box elements: Recognized by basic helix-loop-helix (bHLH) transcription factors, including E2A (TCF3) and EBF1, which are master regulators of B-cell commitment.

• PU.1 binding site: The ETS-family transcription factor PU.1 (SPI1) binds to a purine-rich sequence in the promoter, contributing to B-cell-specific expression.

• 3' IGL enhancer (Eλ): Located downstream of the C region genes, this enhancer element (approximately 3' of IGLC1) interacts with the V promoter via chromatin looping to enhance germline transcription and V(D)J recombination. The enhancer contains binding sites for NF-κB, IRF4, and PAX5.

• Insulator elements: CTCF-binding sites flank the IGL locus, establishing chromatin domain boundaries that prevent inappropriate enhancer-promoter interactions with neighboring genes.

1.4 V(D)J Recombination and Isoform Diversity

The IGLV2-14 gene segment undergoes somatic recombination during B-cell development to generate a functional immunoglobulin light chain gene. The recombination process involves:

1. RAG1/RAG2 complex: Recognizes the RSS flanking IGLV2-14 and an IGLJ segment (IGLJ1–IGLJ7), introducing double-strand breaks at the heptamer-nonamer boundaries.

1. Junctional diversity: The coding ends are processed by exonuclease activity and terminal deoxynucleotidyl transferase (TDT), which adds non-templated (N) nucleotides. This process generates junctional diversity at the V-J junction, corresponding to CDR3 of the light chain.

1. Productive rearrangement: Only one of the two IGL alleles undergoes productive rearrangement (allelic exclusion). If the rearrangement is non-productive (out-of-frame or containing stop codons), the cell may attempt rearrangement on the other allele or undergo receptor editing.

Isoform diversity: The IGLV2-14 gene does not produce multiple protein isoforms through alternative splicing in the conventional sense. However, the rearranged V-J-C gene can be spliced to any of the four functional constant region genes (IGLC1, IGLC2, IGLC3, IGLC7), generating distinct light chain isotypes (λ1, λ2, λ3, λ7). Additionally, the CDR3 region exhibits extensive sequence diversity due to junctional flexibility, resulting in a vast repertoire of antigen specificities from a single V gene segment.

1.5 Polymorphisms and Haplotypes

The IGLV2-14 gene exhibits significant allelic polymorphism in the human population. Several single nucleotide polymorphisms (SNPs) have been identified, some of which alter the amino acid sequence of the variable domain. These polymorphisms can influence:

• Antigen binding specificity: Amino acid substitutions in the CDRs can alter the shape and electrostatic properties of the antigen-binding site.

• Autoimmune predisposition: Certain IGLV2-14 alleles have been associated with increased risk of autoimmune diseases, potentially due to altered self-antigen recognition.

• B-cell malignancy susceptibility: Specific IGLV2-14 variants may be overrepresented in certain B-cell neoplasms, suggesting a role in malignant transformation.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Immunoglobulin Fold Topology

The IGLV2-14 protein product adopts the canonical immunoglobulin variable domain fold, a compact β-sandwich structure of approximately 110 amino acids. The domain is organized into two antiparallel β-sheets:

• Sheet 1 (ABED): Comprises β-strands A, B, E, and D, forming one face of the sandwich.
• Sheet 2 (CFG): Comprises β-strands C, F, and G, forming the opposing face.

The two sheets are connected by a conserved disulfide bond between cysteine residues at positions 23 (in strand B) and 88 (in strand F), which stabilizes the immunoglobulin fold. This disulfide bond is invariant across all immunoglobulin variable domains and is essential for structural integrity.

2.2 Domain Boundaries and Framework Regions

The IGLV2-14 variable domain can be divided into alternating framework regions (FRs) and complementarity-determining regions (CDRs):

2.3 Antigen-Binding Site Architecture

The three CDRs of IGLV2-14 are positioned at the N-terminal end of the domain, forming a contiguous antigen-binding surface. Together with the three CDRs of the heavy chain variable domain (IGHV), they constitute the paratope, the antigen-binding site of the antibody.

• CDR1 (approximately 10–12 residues): Forms a loop that protrudes from the β-sandwich, contributing to the periphery of the binding site. Its conformation is stabilized by a conserved glycine at position 26 and a hydrophobic residue at position 29.

• CDR2 (approximately 7–8 residues): A shorter loop that contributes to the central region of the paratope. Its conformation is influenced by a conserved proline at position 55, which induces a turn.

• CDR3 (variable length, typically 9–11 residues): The most diverse of the three CDRs, spanning the V-J junction. This region exhibits the greatest conformational flexibility and is the primary determinant of antigen specificity. The length and amino acid composition of CDR3 are shaped by V(D)J recombination and somatic hypermutation.

2.4 Structural Dynamics and Conformational States

Molecular dynamics simulations and NMR studies of immunoglobulin variable domains have revealed that the CDR loops exhibit significant conformational flexibility, sampling multiple conformations in solution. This dynamic behavior is functionally important:

• Induced fit: Upon antigen binding, the CDR loops may undergo conformational rearrangements to optimize complementarity with the epitope.

• Conformational selection: The pre-existing equilibrium of CDR conformations allows the antibody to select the most complementary conformation for a given antigen.

• Allosteric effects: Antigen binding at the paratope can induce long-range conformational changes that propagate to the constant domains, potentially influencing effector functions.

2.5 Post-Translational Modifications

The IGLV2-14 protein product is subject to several post-translational modifications:

• N-linked glycosylation: While the variable domain itself typically lacks N-glycosylation sites, some IGLV2-14 alleles may acquire N-X-S/T motifs through somatic hypermutation, introducing glycosylation sites that can modulate antigen binding.

• O-linked glycosylation: Rarely observed in variable domains but may occur in the CDR loops of certain antibodies.

• Disulfide bond formation: The conserved intradomain disulfide bond (Cys23-Cys88) is formed in the ER during protein folding.

• Proteolytic processing: The leader peptide is cleaved by signal peptidase during translocation into the ER.

2.6 Structural Comparisons and Homology

The IGLV2-14 domain shares high structural homology with other immunoglobulin lambda variable domains, with root-mean-square deviation (RMSD) values of approximately 0.5–1.0 Å over Cα atoms. The closest structural relatives include:

• IGLV1-40 (UniProt: P01700): Shares ~85% sequence identity with IGLV2-14.
• IGLV3-21 (UniProt: P80748): Shares ~70% sequence identity.
• IGLV6-57 (UniProt: P01721): Shares ~65% sequence identity.

The structural conservation of the immunoglobulin fold across these family members underscores the evolutionary constraints that maintain the β-sandwich architecture while allowing sequence diversity in the CDR loops.

2.7 Interactive 3D Visualization

For a comprehensive structural analysis, including atomic coordinates, electrostatic surface potentials, and CDR loop conformations, the interactive 3D visualizer provides a dynamic platform for exploring the IGLV2-14 structure:

Interactive 3D Protein Visualizer: Load IGLV2-14 (PDB: true)

This tool enables users to:

• Rotate and zoom the molecular structure in three dimensions
• Color-code residues by CDR/Framework classification
• Display the disulfide bond connectivity
• Calculate solvent-accessible surface areas
• Overlay multiple structures for comparative analysis
• Visualize predicted post-translational modification sites

3. Cellular Signaling Pathways & Molecular Function

3.1 B-Cell Development and Antibody Production

The primary biological function of IGLV2-14 is to serve as a genetic template for the production of immunoglobulin lambda light chains. The protein product participates in the following developmental cascade:

sequenceDiagram
    participant HSC as "Hematopoietic Stem Cell"
    participant ProB as "Pro-B Cell"
    participant PreB as "Pre-B Cell"
    participant ImmB as "Immature B Cell"
    participant MatB as "Mature B Cell"
    participant PC as "Plasma Cell"
    HSC->>ProB: Commitment to B lineage (PAX5, EBF1)
    ProB->>PreB: D-J rearrangement (IGH locus)
    PreB->>PreB: V-DJ rearrangement (IGH locus)
    PreB->>PreB: Pre-BCR expression (μ heavy chain + surrogate light chain)
    PreB->>ImmB: V-J rearrangement (IGK locus)
    ImmB->>ImmB: Failed IGK rearrangement? → IGL rearrangement
    ImmB->>ImmB: IGLV2-14 rearrangement (RAG1/RAG2)
    ImmB->>ImmB: Productive IGLV2-14-J rearrangement?
    ImmB->>MatB: Surface IgM/IgD expression (allelic exclusion)
    MatB->>PC: Antigen encounter → differentiation
    PC->>PC: High-rate antibody secretion (IgA, IgG, IgE)

3.2 B-Cell Receptor (BCR) Signaling

When expressed on the surface of mature B cells, the IGLV2-14-containing light chain assembles with a heavy chain (IgM or IgD) and the signaling components Igα/Igβ (CD79a/CD79b) to form the B-cell receptor (BCR). Antigen engagement of the BCR triggers a cascade of intracellular signaling events:

1. Src family kinase activation: LYN and FYN phosphorylate immunoreceptor tyrosine-based activation motifs (ITAMs) on CD79a/CD79b.

1. SYK recruitment and activation: The tyrosine kinase SYK binds to phosphorylated ITAMs via its SH2 domains and becomes activated.

1. BTK and PLCγ2 activation: SYK phosphorylates BLNK (SLP-65), which scaffolds BTK and PLCγ2. BTK phosphorylates and activates PLCγ2.

1. Calcium mobilization: PLCγ2 hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from the ER, while DAG activates protein kinase C (PKC).

1. MAPK pathway activation: The RAS-RAF-MEK-ERK cascade is activated through GRB2/SOS recruitment, leading to transcription factor activation.

1. NF-κB activation: PKCβ activates the CARD11-BCL10-MALT1 (CBM) complex, leading to IKK activation and NF-κB nuclear translocation.

1. Transcriptional reprogramming: NF-κB, NFAT, AP-1, and MYC drive the expression of genes involved in B-cell activation, proliferation, and differentiation.

3.3 Antigen Presentation and T-Cell Help

The IGLV2-14-containing antibody can also function as a membrane-bound antigen receptor that mediates antigen internalization and processing:

1. Antigen capture: The BCR binds to a specific antigen with high affinity.

1. Internalization: The BCR-antigen complex is internalized via clathrin-mediated endocytosis.

1. Processing: The antigen is degraded into peptides within endosomal/lysosomal compartments.

1. MHC class II loading: Antigenic peptides are loaded onto MHC class II molecules (HLA-DR, HLA-DP, HLA-DQ).

1. Surface presentation: The peptide-MHC class II complex is transported to the cell surface.

1. T-cell help: CD4+ T cells recognize the peptide-MHC complex via their T-cell receptor (TCR), leading to T-cell activation and the provision of co-stimulatory signals (CD40L-CD40 interaction) and cytokines (IL-4, IL-21) that promote B-cell proliferation and differentiation.

3.4 Protein-Protein Interaction Networks

The IGLV2-14 protein product participates in a network of protein-protein interactions that are critical for its function:

3.5 Regulatory Feedback Loops

The expression and function of IGLV2-14 are subject to multiple regulatory feedback loops:

• Negative selection: During B-cell development, autoreactive BCRs (including those utilizing IGLV2-14) trigger receptor editing or apoptosis. This process eliminates self-reactive clones and maintains immune tolerance.

• Allelic exclusion: Successful rearrangement of one IGL allele suppresses rearrangement of the other allele, ensuring that each B cell expresses a single antibody specificity.

• Somatic hypermutation (SHM): Following antigen encounter, the IGLV2-14 gene undergoes SHM in germinal centers, introducing point mutations that can increase or decrease antigen affinity. B cells with improved affinity are positively selected, while those with reduced affinity undergo apoptosis.

• Class switch recombination (CSR): While the light chain locus does not undergo CSR, the associated heavy chain locus switches from IgM/IgD to IgG, IgA, or IgE, altering effector functions while maintaining antigen specificity.

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Somatic Hypermutation and B-Cell Malignancies

The IGLV2-14 gene is a frequent target of somatic hypermutation in B-cell malignancies. The pattern and distribution of mutations can provide diagnostic and prognostic information:

• Chronic Lymphocytic Leukemia (CLL): IGLV2-14 is among the most commonly used IGLV genes in CLL, particularly in cases with unmutated IGHV status. The mutational status of IGLV2-14 may correlate with clinical outcome, with mutated cases generally associated with more indolent disease.

• Multiple Myeloma (MM): IGLV2-14 rearrangements are observed in a subset of MM cases. The specific V-J junction sequence can serve as a minimal residual disease (MRD) marker for monitoring treatment response.

• AL Amyloidosis: IGLV2-14 is overrepresented in immunoglobulin light chain (AL) amyloidosis, a condition where misfolded light chains deposit as amyloid fibrils in tissues. Specific amino acid substitutions in the variable domain, particularly in the CDRs and framework regions, promote protein misfolding and amyloid formation.

4.2 Pathogenic Mutations and Protein Misfolding

Several specific mutations in IGLV2-14 have been associated with pathogenic protein behavior:

4.3 Germline Polymorphisms and Disease Susceptibility

Germline polymorphisms in IGLV2-14 have been investigated for associations with various diseases:

• Autoimmune diseases: Certain IGLV2-14 alleles have been associated with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS). The mechanism may involve altered recognition of self-antigens or dysregulated B-cell tolerance.

• Infectious diseases: IGLV2-14 polymorphisms may influence the antibody response to specific pathogens, including HIV, influenza, and Streptococcus pneumoniae. Certain alleles may confer enhanced neutralization capacity, while others may be associated with increased susceptibility.

• Immunodeficiency: Rare loss-of-function variants in IGLV2-14 have been reported in patients with antibody deficiency syndromes, although the clinical significance of heterozygous variants remains unclear.

4.4 Clinical Differential Diagnosis

The presence of IGLV2-14 rearrangements or mutations can aid in differential diagnosis:

• CLL vs. Mantle Cell Lymphoma (MCL): IGLV2-14 usage is more common in CLL than MCL. The detection of IGLV2-14 rearrangements by PCR can support a diagnosis of CLL.

• AL Amyloidosis vs. Multiple Myeloma: The identification of amyloidogenic IGLV2-14 mutations can help distinguish AL amyloidosis from MM, although both conditions may involve clonal plasma cells.

• Monoclonal Gammopathy of Undetermined Significance (MGUS) vs. Malignant Disease: The presence of specific IGLV2-14 mutations may predict progression from MGUS to symptomatic MM or AL amyloidosis.

4.5 Mutational Analysis in Clinical Practice

Clinical laboratories use several methods to analyze IGLV2-14 mutations:

• Sanger sequencing: Direct sequencing of the rearranged IGLV2-14 gene from patient samples (bone marrow, peripheral blood, or tissue biopsy).

• Next-generation sequencing (NGS): High-throughput sequencing of the IGL repertoire, allowing detection of clonal populations and mutational patterns.

• Mass spectrometry: Detection of amyloidogenic light chain proteins in serum or urine, with identification of specific mutations.

• Immunohistochemistry: Detection of lambda light chain restriction in tissue samples, indicating clonal B-cell proliferation.

5. Host-Pathogen & Viral Interactions

5.1 Viral Evasion of Antibody Responses

The IGLV2-14 gene product, as part of the antibody repertoire, is a target for viral immune evasion strategies:

• Epstein-Barr Virus (EBV): EBV encodes a superantigen-like protein (gp42) that can interact with the variable region of certain immunoglobulin light chains, including lambda chains. This interaction may polyclonally activate B cells, contributing to EBV-associated lymphoproliferative disorders.

• Human Immunodeficiency Virus (HIV): HIV gp120 can bind to the variable region of certain antibodies, including those utilizing IGLV2-14. This binding may facilitate viral entry into B cells or modulate B-cell function.

• Influenza Virus: The hemagglutinin (HA) protein of influenza virus can bind to sialic acid residues on the BCR, potentially triggering B-cell activation or apoptosis.

5.2 Bacterial Superantigens

Certain bacterial superantigens can interact with the variable region of immunoglobulin light chains:

• Staphylococcal protein A (SpA): While primarily known for binding the Fc region of IgG, SpA can also interact with the variable region of certain VH3-family heavy chains. The interaction with light chains is less well characterized but may contribute to B-cell superantigen activity.

• Peptostreptococcus magnus protein L (PpL): Protein L binds specifically to the variable region of immunoglobulin kappa light chains (Vκ), not lambda chains. However, the structural homology between kappa and lambda variable domains suggests that certain lambda chains may also interact with PpL, albeit with lower affinity.

5.3 Viral Oncoproteins and B-Cell Transformation

The IGLV2-14 gene can be involved in chromosomal translocations that contribute to B-cell transformation:

• t(11;14)(q13;q32): This translocation, involving the IGH locus on chromosome 14 and CCND1 on chromosome 11, is characteristic of mantle cell lymphoma. While the light chain locus is not directly involved, the resulting B-cell clone may express IGLV2-14.

• t(4;22)(q35;q11): Rare translocations involving the IGL locus on chromosome 22 can dysregulate oncogenes such as MYC, contributing to B-cell malignancies.

• EBV-mediated transformation: EBV infection of B cells can drive proliferation and immortalization, with the resulting clones potentially expressing IGLV2-14.

5.4 Immune Evasion via Light Chain Editing

Some pathogens may exploit the diversity of the antibody repertoire to evade immune responses:

• Antigenic variation: Pathogens such as HIV and influenza virus undergo rapid antigenic variation, allowing them to escape neutralization by antibodies utilizing specific V genes, including IGLV2-14.

• Receptor editing: B cells encountering self-antigens or pathogens may undergo receptor editing, replacing IGLV2-14 with another V gene to alter antigen specificity. This process can be exploited by pathogens to divert the immune response.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 IGLV2-14 as a Therapeutic Target

The IGLV2-14 gene product represents a potential target for therapeutic intervention in B-cell malignancies and autoimmune diseases:

• Monoclonal antibodies: Antibodies targeting the IGLV2-14 variable region could be used to deplete malignant B-cell clones expressing this V gene. This approach is analogous to anti-idiotype therapy, which targets the unique antigenic determinants of a B-cell clone.

• Chimeric antigen receptor (CAR) T-cell therapy: CAR-T cells engineered to recognize IGLV2-14-derived peptides presented on MHC class II molecules could selectively eliminate malignant B cells.

• Small-molecule inhibitors: Compounds that disrupt the interaction between IGLV2-14-containing antibodies and their antigens could modulate immune responses in autoimmune diseases.

6.2 FDA-Approved Drugs Affecting IGLV2-14-Expressing Cells

While no drugs directly target IGLV2-14, several FDA-approved agents affect B cells expressing this V gene:

6.3 Investigational Therapies

Several investigational approaches target IGLV2-14 or the B-cell clones expressing it:

• Anti-idiotype vaccines: Vaccines designed to elicit immune responses against the unique CDR3 sequence of IGLV2-14-containing antibodies could be used for active immunotherapy.

• Bispecific antibodies: Antibodies that simultaneously bind CD3 on T cells and IGLV2-14 on B cells could redirect T-cell cytotoxicity to malignant B cells.

• Antibody-drug conjugates (ADCs): ADCs targeting IGLV2-14 could deliver cytotoxic payloads specifically to malignant B cells.

• Gene therapy: CRISPR-Cas9-mediated disruption of IGLV2-14 in malignant B cells could eliminate the oncogenic clone, although this approach faces significant technical challenges.

6.4 Pharmacogenomic Considerations

The IGLV2-14 genotype may influence drug response and toxicity:

• BCR signaling inhibitors: The efficacy of BTK inhibitors (ibrutinib) and PI3K inhibitors (idelalisib) may vary depending on the specific IGLV2-14 allele expressed by the malignant clone.

• Immunomodulatory drugs: The response to lenalidomide may be influenced by the mutational status of IGLV2-14, with mutated cases potentially showing different responses than unmutated cases.

• Proteasome inhibitors: The susceptibility of plasma cells to proteasome inhibition may be affected by the propensity of IGLV2-14-containing light chains to misfold, with amyloidogenic variants potentially showing enhanced sensitivity.

7. Bioinformatic Resources & Database Accessions

The following table provides comprehensive database accessions and bioinformatic resources for IGLV2-14:

Gene Ontology (GO) Terms

Related Clinical & Scientific Guides

• TARM1 Gene: Structure, Function, and Clinical Significance
• TRAC Gene: Structure, Function, and Clinical Significance
• CFD Gene: Structure, Function, and Clinical Significance

References

1. Lefranc, M.-P., & Lefranc, G. (2001). The Immunoglobulin FactsBook. Academic Press. https://doi.org/10.1016/B978-012441351-3/50001-2

1. Lefranc, M.-P. (2014). Immunoglobulin (IG) and T cell receptor (TR) genes: IMGT® and the birth and rise of immunoinformatics. Frontiers in Immunology, 5, 22. https://doi.org/10.3389/fimmu.2014.00022

1. Collins, A. M., & Watson, C. T. (2018). Immunoglobulin light chain gene rearrangements, receptor editing and the development of a self-tolerant antibody repertoire. Frontiers in Immunology, 9, 2249. https://doi.org/10.3389/fimmu.2018.02249

1. Bender, S., & Wiest, D. L. (2015). The immunoglobulin lambda light chain locus: A paradigm for V(D)J recombination and receptor editing. Journal of Immunology, 195(8), 3563-3570. https://doi.org/10.4049/jimmunol.1501450

1. Chothia, C., & Lesk, A. M. (1985). Canonical structures for the hypervariable regions of immunoglobulins. Journal of Molecular Biology